{"id":46906,"date":"2022-08-03T20:01:54","date_gmt":"2022-08-03T18:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/as-congress-debates-whether-to-cap-insulin-pricing-medicare-advisor-chapter-issues-state-by-state-analysis-confirming-major-inequity-in-insulin-access-and-costs-for-medicare-beneficiaries\/"},"modified":"2022-08-03T20:01:54","modified_gmt":"2022-08-03T18:01:54","slug":"as-congress-debates-whether-to-cap-insulin-pricing-medicare-advisor-chapter-issues-state-by-state-analysis-confirming-major-inequity-in-insulin-access-and-costs-for-medicare-beneficiaries","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/as-congress-debates-whether-to-cap-insulin-pricing-medicare-advisor-chapter-issues-state-by-state-analysis-confirming-major-inequity-in-insulin-access-and-costs-for-medicare-beneficiaries\/","title":{"rendered":"\u00a0As Congress Debates Whether to Cap Insulin Pricing, Medicare Advisor Chapter Issues State-by-State Analysis Confirming Major Inequity in Insulin Access and Costs for Medicare Beneficiaries"},"content":{"rendered":"
\n

\n\u00a0Analysis finds that patients in some states pay nearly 26% of median income for their life-saving insulin<\/i>\n<\/p>\n

\nMedicare coverage options vary by state, making it even more critical to choose the right plan, as it could save patients with diabetes thousands of dollars<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Chapter<\/a>, the leading data-driven Medicare Advisor, has today issued a new study on the average cost of two forms of insulin, finding that the average cost of insulin varies greatly by which state one lives in, with out-of-pocket costs for Medicare beneficiaries as high as $10,689 per year, or roughly 26% of their median annual income.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThis study highlights the growing crisis for American [seniors] who have diabetes and are paying a large part of their income to access a life-saving drug,\u201d said Cobi Blumenfeld-Gantz, co-founder and CEO of Chapter. \u201cAs Chapter\u2019s analysis shows, capping insulin costs for Medicare beneficiaries would dramatically improve the health and financial well-being of those who rely on insulin treatment and who do not have the requisite coverage through their Medicare plan. The data also shows significant variation of insulin costs based on geography \u2013 and one\u2019s ability to pay for their medications shouldn\u2019t depend on where they live.\u201d\n<\/p>\n

\nFor this analysis, Chapter\u2019s data team examined two of the most popular insulin drugs used to treat people with diabetes and compared the annual cost of insulin for all available Medicare plans (Medicare Part D Plans and Medicare Advantage Prescription Drug plans). The team analyzed the latest prescription drug prices for 2022 in the most populous ZIP codes in each state and Washington DC and paired this data with pharmacy-specific pricing in these ZIP codes. To compare insulin prices with income, the data team used the median income in every state adjusting for households of all sizes and incomes.\n<\/p>\n

\nA table of state-by-state analysis follows below, and the complete analysis can be found at [https:\/\/askchapter.org\/magazine\/senior-health-wellness\/medicare-resources\/state-insulin-costs<\/a>]\n<\/p>\n

\nThe findings highlight three issues with current insulin pricing and coverage options across America:\n<\/p>\n